{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:26:03Z","timestamp":1789043163316,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030052"],"award-info":[{"award-number":["82030052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171985"],"award-info":[{"award-number":["82171985"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hubei Province Science and Technology Innovation Team","award":["[2022] No. 72"],"award-info":[{"award-number":["[2022] No. 72"]}]},{"name":"Key Project of Hubei Province Natural Science Foundation","award":["No. 2021CFA008"],"award-info":[{"award-number":["No. 2021CFA008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00259-024-06973-7","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:47:20Z","timestamp":1732171640000},"page":"1278-1290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["[68Ga]Ga-PSMA-617 PET\/MRI for imaging patients suspected of hepatocellular carcinoma"],"prefix":"10.1007","volume":"52","author":[{"given":"Chunxia","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangmeihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Gai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chidan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7263-7399","authenticated-orcid":false,"given":"Xiaoli","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"6973_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"6973_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380:1450\u201362. https:\/\/doi.org\/10.1056\/NEJMra1713263.","journal-title":"N Engl J Med"},{"key":"6973_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"key":"6973_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"key":"6973_CR5","doi-asserted-by":"publisher","unstructured":"Lin J, Zhang H, Yu H, et al. Epidemiological characteristics of primary liver cancer in Mainland China from 2003 to 2020: a representative multicenter study. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.906778.","DOI":"10.3389\/fonc.2022.906778"},{"key":"6973_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/s43018-023-00618-8","volume":"4","author":"H Zeng","year":"2023","unstructured":"Zeng H, Cao M, Xia C, et al. Performance and effectiveness of hepatocellular carcinoma screening in individuals with HBsAg seropositivity in China: a multicenter prospective study. Nat Cancer. 2023;4:1382\u201394. https:\/\/doi.org\/10.1038\/s43018-023-00618-8.","journal-title":"Nat Cancer"},{"key":"6973_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of primary Liver Cancer (2022 Edition). Liver Cancer. 2023;12:405\u201344. https:\/\/doi.org\/10.1159\/000530495.","journal-title":"Liver Cancer"},{"key":"6973_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, et al. Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:541\u201365. https:\/\/doi.org\/10.6004\/jnccn.2021.0022.","journal-title":"J Natl Compr Canc Netw"},{"key":"6973_CR9","doi-asserted-by":"publisher","first-page":"109404","DOI":"10.1016\/j.ejrad.2020.109404","volume":"134","author":"Y Liang","year":"2021","unstructured":"Liang Y, Xu F, Guo Y, et al. Diagnostic performance of LI-RADS for MRI and CT detection of HCC: a systematic review and diagnostic meta-analysis. Eur J Radiol. 2021;134:109404. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109404.","journal-title":"Eur J Radiol"},{"key":"6973_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/jmri.27553","volume":"55","author":"HR Bello","year":"2022","unstructured":"Bello HR, Mahdi ZK, Lui SK, Nandwana SB, Harri PA, Davarpanah AH. Hepatocellular Carcinoma with atypical imaging features: review of the morphologic hepatocellular carcinoma subtypes with radiology-pathology correlation. J Magn Reson Imaging. 2022;55:681\u201397. https:\/\/doi.org\/10.1002\/jmri.27553.","journal-title":"J Magn Reson Imaging."},{"key":"6973_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3892\/or.2013.2886","volume":"31","author":"K Izuishi","year":"2014","unstructured":"Izuishi K, Yamamoto Y, Mori H, et al. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer. Oncol Rep. 2014;31:701\u20136. https:\/\/doi.org\/10.3892\/or.2013.2886.","journal-title":"Oncol Rep"},{"key":"6973_CR12","doi-asserted-by":"publisher","first-page":"101099","DOI":"10.1016\/j.jhepr.2024.101099","volume":"6","author":"KWH Chiu","year":"2024","unstructured":"Chiu KWH, Chiang CL, Chan KSK, et al. Dual-tracer PET\/CT in the management of hepatocellular carcinoma. JHEP Rep. 2024;6:101099. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101099.","journal-title":"JHEP Rep"},{"key":"6973_CR13","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1007\/s00259-017-3724-2","volume":"44","author":"S Li","year":"2017","unstructured":"Li S, Peck-Radosavljevic M, Ubl P, et al. The value of [11\u00a0C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. Eur J Nucl Med Mol Imaging. 2017;44:1732\u201341. https:\/\/doi.org\/10.1007\/s00259-017-3724-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6973_CR14","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00259-015-3241-0","volume":"43","author":"MA Castilla-Li\u00e8vre","year":"2016","unstructured":"Castilla-Li\u00e8vre MA, Franco D, Gervais P, et al. Diagnostic value of combining \u00b9\u00b9C-choline and 18F-FDG PET\/CT in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:852\u20139. https:\/\/doi.org\/10.1007\/s00259-015-3241-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6973_CR15","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res. 1994;54:1807\u201311.","journal-title":"Cancer Res"},{"key":"6973_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-y","volume":"1","author":"GL Wright Jr","year":"1995","unstructured":"Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18\u201328. https:\/\/doi.org\/10.1016\/1078-1439(95)00002-y.","journal-title":"Urol Oncol"},{"key":"6973_CR17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2967\/jnumed.120.257238","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, et al. Current and emerging clinical applications of PSMA PET Diagnostic imaging for prostate Cancer. J Nucl Med. 2021;62:596\u2013604. https:\/\/doi.org\/10.2967\/jnumed.120.257238.","journal-title":"J Nucl Med"},{"key":"6973_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"6973_CR19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1097\/PAS.0000000000001971","volume":"46","author":"M Kmeid","year":"2022","unstructured":"Kmeid M, Park YN, Chung T, et al. PSMA immunohistochemistry in hepatic neoplasms: a promising diagnostic marker with potential theranostic applications. Am J Surg Pathol. 2022;46:1688\u201399. https:\/\/doi.org\/10.1097\/PAS.0000000000001971.","journal-title":"Am J Surg Pathol"},{"key":"6973_CR20","doi-asserted-by":"publisher","first-page":"7664","DOI":"10.1002\/hep4.1861","volume":"26","author":"LX Chen","year":"2020","unstructured":"Chen LX, Zou SJ, Li D, et al. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis. World J Gastroenterol. 2020;26:7664\u201378. https:\/\/doi.org\/10.1002\/hep4.1861.","journal-title":"World J Gastroenterol"},{"key":"6973_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2967\/jnumed.118.214833","volume":"60","author":"M Kesler","year":"2019","unstructured":"Kesler M, Levine C, Hershkovitz D, et al. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. 2019;60:185\u201391. https:\/\/doi.org\/10.2967\/jnumed.118.214833.","journal-title":"J Nucl Med"},{"key":"6973_CR22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2967\/jnumed.120.257915","volume":"62","author":"N Hirmas","year":"2021","unstructured":"Hirmas N, Leyh C, Sraieb M, et al. 68Ga-PSMA-11 PET\/CT Improves tumor detection and impacts management in patients with hepatocellular carcinoma. J Nucl Med. 2021;62:1235\u201341. https:\/\/doi.org\/10.2967\/jnumed.120.257915.","journal-title":"J Nucl Med."},{"key":"6973_CR23","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep4.1861","volume":"6","author":"SM Thompson","year":"2022","unstructured":"Thompson SM, Suman G, Torbenson MS, et al. PSMA as a theranostic target in hepatocellular carcinoma: immunohistochemistry and 68 Ga-PSMA-11 PET using cyclotron-produced 68 Ga. Hepatol Commun. 2022;6:1172\u201385. https:\/\/doi.org\/10.1002\/hep4.1861.","journal-title":"Hepatol Commun"},{"key":"6973_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/RLU.0000000000002701","volume":"44","author":"S Kuyumcu","year":"2019","unstructured":"Kuyumcu S, Has-Simsek D, Iliaz R, et al. Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET\/CT. Clin Nucl Med. 2019;44:702\u20136. https:\/\/doi.org\/10.1097\/RLU.0000000000002701.","journal-title":"Clin Nucl Med"},{"key":"6973_CR25","doi-asserted-by":"publisher","first-page":"5638283","DOI":"10.1155\/2018\/5638283","volume":"2018","author":"SJ Hectors","year":"2018","unstructured":"Hectors SJ, Wagner M, Besa C, Huang W, Taouli B, Multiparametric. FDG-PET\/MRI of Hepatocellular Carcinoma: initial experience. Contrast Media Mol Imaging. 2018;2018:5638283. https:\/\/doi.org\/10.1155\/2018\/5638283.","journal-title":"Contrast Media Mol Imaging"},{"key":"6973_CR26","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","volume":"351","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. https:\/\/doi.org\/10.1136\/bmj.h5527.","journal-title":"BMJ"},{"key":"6973_CR27","doi-asserted-by":"publisher","first-page":"657619","DOI":"10.3389\/fmed.2021.657619","volume":"8","author":"C Qin","year":"2021","unstructured":"Qin C, Gai Y, Liu Q, et al. Optimized application of (68)Ga-Prostate-specific membrane Antigen-617 whole-body PET\/CT and pelvic PET\/MR in prostate cancer initial diagnosis and staging. Front Med (Lausanne). 2021;8:657619. https:\/\/doi.org\/10.3389\/fmed.2021.657619.","journal-title":"Front Med (Lausanne)"},{"key":"6973_CR28","doi-asserted-by":"publisher","first-page":"110784","DOI":"10.1016\/j.ejrad.2023.110784","volume":"162","author":"Y Feng","year":"2023","unstructured":"Feng Y, Zhang H, Ren Q, et al. Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment. Eur J Radiol. 2023;162:110784. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110784.","journal-title":"Eur J Radiol"},{"key":"6973_CR29","doi-asserted-by":"publisher","first-page":"110911","DOI":"10.1016\/j.ejrad.2023.110911","volume":"165","author":"H Chen","year":"2023","unstructured":"Chen H, Wang J, Guo T, et al. A gadoxetic-acid enhancement flux analysis of small liver nodules (\u2264\u20092\u00a0cm) in patients at high risk of hepatocellular carcinoma. Eur J Radiol. 2023;165:110911. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110911.","journal-title":"Eur J Radiol"},{"key":"6973_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/jmri.24937","volume":"43","author":"A Shah","year":"2016","unstructured":"Shah A, Tang A, Santillan C, Sirlin C. Cirrhotic liver: what\u2019s that nodule? The LI-RADS approach. J Magn Reson Imaging. 2016;43:281\u201394. https:\/\/doi.org\/10.1002\/jmri.24937.","journal-title":"J Magn Reson Imaging"},{"key":"6973_CR31","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.3390\/cancers15133393","volume":"15","author":"L Cerrito","year":"2023","unstructured":"Cerrito L, Ainora ME, Borriello R, et al. Contrast-enhanced imaging in the management of Intrahepatic Cholangiocarcinoma: state of art and future perspectives. Cancers (Basel). 2023;15:3393. https:\/\/doi.org\/10.3390\/cancers15133393.","journal-title":"Cancers (Basel)"},{"key":"6973_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11547-020-01185-z","volume":"125","author":"RP Mathew","year":"2020","unstructured":"Mathew RP, Sam M, Raubenheimer M, Patel V, Low G. Hepatic hemangiomas: the various imaging avatars and its mimickers. Radiol Med. 2020;125:801\u201315. https:\/\/doi.org\/10.1007\/s11547-020-01185-z.","journal-title":"Radiol Med"},{"key":"6973_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejca.2008.10.028","volume":"45","author":"LH Schwartz","year":"2009","unstructured":"Schwartz LH, Bogaerts J, Ford R, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.028.","journal-title":"Eur J Cancer"},{"key":"6973_CR34","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1007\/s00330-020-07572-4","volume":"31","author":"FHJ Elsholtz","year":"2021","unstructured":"Elsholtz FHJ, Asbach P, Haas M, et al. Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur Radiol. 2021;31:6116\u201324. https:\/\/doi.org\/10.1007\/s00330-020-07572-4.","journal-title":"Eur Radiol"},{"key":"6973_CR35","doi-asserted-by":"publisher","first-page":"e96801","DOI":"10.1371\/journal.pone.0096801","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A. IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9:e96801. https:\/\/doi.org\/10.1371\/journal.pone.0096801.","journal-title":"PLoS ONE"},{"key":"6973_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/1097-0142(19950815)76:4<579::aid-cncr2820760407>3.0.co;2-d","volume":"76","author":"UC Nzeako","year":"1995","unstructured":"Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of north American patients with hepatocellular carcinoma. Cancer. 1995;76:579\u201388. https:\/\/doi.org\/10.1002\/1097-0142(19950815)76:4<579::aid-cncr2820760407>3.0.co;2-d.","journal-title":"Cancer"},{"key":"6973_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","volume":"85","author":"M Corpetti","year":"2024","unstructured":"Corpetti M, M\u00fcller C, Beltran H, de Bono J, Theurillat JP. Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes. Eur Urol. 2024;85:193\u2013204. https:\/\/doi.org\/10.1016\/j.eururo.2023.11.018.","journal-title":"Eur Urol"},{"key":"6973_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.14670\/HH-18-215","volume":"35","author":"C Van de Wiele","year":"2020","unstructured":"Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919\u201327. https:\/\/doi.org\/10.14670\/HH-18-215.","journal-title":"Histol Histopathol"},{"key":"6973_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12149-023-01876-3","volume":"38","author":"SA Shamim","year":"2024","unstructured":"Shamim SA, Kumar N, Arora G, et al. A prospective study of 68Ga-PSMA PET\/CT imaging of HCC as diagnosed on conventional imaging to evaluate for potential 177Lu-PSMA therapy. Ann Nucl Med. 2024;38:103\u201311. https:\/\/doi.org\/10.1007\/s12149-023-01876-3.","journal-title":"Ann Nucl Med"},{"key":"6973_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14309\/ctg.0000000000000041","volume":"10","author":"D Jiao","year":"2019","unstructured":"Jiao D, Li Y, Yang F, et al. Expression of prostate-specific membrane antigen in tumor-associated vasculature predicts poor prognosis in Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2019;10:1\u20137. https:\/\/doi.org\/10.14309\/ctg.0000000000000041.","journal-title":"Clin Transl Gastroenterol"},{"key":"6973_CR41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00259-020-05017-0","volume":"48","author":"J Kunikowska","year":"2021","unstructured":"Kunikowska J, Cie\u015blak B, Gierej B, et al. [68 Ga]Ga-Prostate-specific membrane Antigen PET\/CT: a novel method for imaging patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:883\u201392. https:\/\/doi.org\/10.1007\/s00259-020-05017-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6973_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.001.","journal-title":"J Hepatol"},{"key":"6973_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00259-019-04452-y","volume":"47","author":"ME Mayerhoefer","year":"2020","unstructured":"Mayerhoefer ME, Prosch H, Beer L, et al. PET\/MRI versus PET\/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging. 2020;47:51\u201360. https:\/\/doi.org\/10.1007\/s00259-019-04452-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6973_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jceh.2016.08.012","volume":"6","author":"S Shankar","year":"2016","unstructured":"Shankar S, Kalra N, Bhatia A, et al. Role of Diffusion Weighted Imaging (DWI) for Hepatocellular Carcinoma (HCC) detection and its grading on 3T MRI: a prospective study. J Clin Exp Hepatol. 2016;6:303\u201310. https:\/\/doi.org\/10.1016\/j.jceh.2016.08.012.","journal-title":"J Clin Exp Hepatol"},{"key":"6973_CR45","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s00259-023-06155-x","volume":"50","author":"Q Lu","year":"2023","unstructured":"Lu Q, Long Y, Gai Y, Liu Q, Jiang D, Lan X. [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy. Eur J Nucl Med Mol Imaging. 2023;50:2342\u201352. https:\/\/doi.org\/10.1007\/s00259-023-06155-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6973_CR46","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.123.266391","volume":"65","author":"A Farolfi","year":"2024","unstructured":"Farolfi A, Armstrong WR, Djaileb L, et al. Differences and common ground in 177Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers. J Nucl Med. 2024;65:438\u201345. https:\/\/doi.org\/10.2967\/jnumed.123.266391.","journal-title":"J Nucl Med"},{"key":"6973_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06973-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:55:14Z","timestamp":1739962514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06973-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6973"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06973-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This single-center study (NCT05006326)\u00a0was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethical Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (No.2021-0606).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0,  and  and Figs.\u00a0-.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Chunxia Qin and Xiaoli Lan serve as editors for this journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}